Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Take a look at the 1-year chart of Aimmune (NASDAQ: AIMT) with the added notations: AIMT has a key level of support at $28 (green). The stock looks like its making its way back… Continue Reading »